Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

MIR150

Written2016-12Monireh Arjmand
Department of Biology, Faculty of Science, Payame Noor University, Tehran, Iran. bhr.arjmand@gmail.com

Abstract MicroRNAs (miRNAs) are a class of small regulatory RNAs (20-23 nucleotides long) that have been found to play a critical role in the wide spectrum of biological processes. These small endogenous noncoding RNAs are able to negatively regulate gene expression by pairing with the 3'-untranslated region (3'-UTR) of their target mRNA. miR-150 is a short and single-stranded miRNA, encoded by a gene located at 19q13.33 in Homo sapiens, which is processed to two mature forms (miR-150-5p and miR-150-3p). It has proven to be a pivotal miRNA engaged in the development of hematologic malignancies, normal haematopoiesis, differentiation of B and T cells, and a number of tumours including breast, osteosarcoma, lung, gastric cancer and etc.

Keywords MicroRNAs, has-miR-150

(Note : for Links provided by Atlas : click)

Identity

Alias_namesMIRN150
Alias_symbol (synonym)hsa-mir-150
Other alias
HGNC (Hugo) MIR150
LocusID (NCBI) 406942
Atlas_Id 50556
Location 19q13.33  [Link to chromosome band 19q13]
Location_base_pair Starts at 49500785 and ends at 49500868 bp from pter ( according to hg19-Feb_2009)  [Mapping MIR150.png]
Local_order chr19: 49500785-49500868 (according to GRCh38). Based on Mapviewer Genes on Sequence, genes surrounding the MIR150 on 19q13.33 includes:
 
Fusion genes
(updated 2017)
Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands)

DNA/RNA

 
Description RNA polymerase II produces the primary miRNA transcripts (Lee et al., ?2004) what will result in hairpin loop structures by microprocessor complex (Cai et al., ?2004; Lee et al., ?2003; Gregory et al., ?2006). The stem-loop structure has a two-nucleotide overhang at its 3' end and termed as a pre-miRNA (precursor-miRNA). Pre-miRNAs will be exported to cytoplasm through the nucleocytoplasmic shuttler Exportin-5 (XPO5), in an energy dependent mechanism (Auyeung et al., 2013; Murchison et al., ?2004). In the cytoplasm, the pre-miRNA hairpin is cleaved to a miRNA:miRNA* duplex by the endoribonuclease Dicer (Lund et al., ?2006; Park et al., ?2011). Potentially, either strand of the duplex could be a functional miRNA, however only one strand usually interacts with mRNA target through the RNA-induced silencing complex (RISC) (Filipowicz et al., ?2008). The sequence of has-miRNA-150, through the above mentioned mechanism, will be transcribed to a stem-loop structure (Reuter et al., ?2010) which finally will maturates to MIR150-5p and MIR150-3p.

Protein

Note microRNAs are not translated into amino acids.

Mutations

Note Mutations have not been reported.

Implicated in

Note There are growing reports on regulatory roles of small RNAs including transcriptional gene silencing/activation and post-transcriptional gene silencing events (Thomas et al., 2007; Nassiri et al. 2013a; Nassiri et al. 2013b; Azimzadeh et al., ?2014). The role of MIR150 as an oncogene or tumor suppressor in different tumors and its potential as a tumor biomarker of prognosis, ad for targeted therapeutic strategy, is been investigated (Wang et al., ?2015).
  
Entity Megakaryocytopoiesis
Note MIR150 drives megakaryocyte-erythrocyte progenitors (MEPs) differentiation toward megakaryocytes at the expense of erythroid cells, and the transcription factor MYB is a critical target of MIR150 in this regulation (Lu et al., ?2008). Thrombopoietin ( THPO) down-modulates MYB expression through induction of MIR150 (Barroga et al., ?2008). MIR150 is expressed in mature B and T cells and regulates their differentiation; MIR150 blocks the transition of pro-B to pre-B cells (Xiao et al., ?2007).
  
  
Entity Cell-cell signaling
Note Some cells secrete miRNAs as cell-cell signaling molecules (intercellular/interorgan) (Azimzadeh et al., ?2014). Human THP-1 cells selectively package MIR150 into active microvesicles in vitro. These secreted microvesicles are delivered specifically into human HMEC-1 cells and induce their migration as an inflammatory response (Zhang et al. 2010).
  
  
Entity Pancreatic Cancer
Note MUC4, a member of Mucins family, is a glycoprotein upregulated in pancreatic tumors. Silencing of MUC4 results in the suppression of cell growth and metastasis in pancreatic tumors (Singh et al., ?2004). The binding site of MIR150 is located at the 3' UTR of MUC4, which leads to the downregulation of MUC4 expression. The overexpression of MIR150 mitigates the malignant behavior of pancreatic cancer cells (Srivastava et al., 2011).
  
  
Entity Colorectal cancer
Note In a work aiming to figure out the altered miRNAs in colorectal cancer (CRC) through characterization of the miRNA profiles of serum exosomes, Ogata-Kawata et al. has showed that the serum exosomal levels of seven miRNAs, including MIR150, were significantly higher in primary CRC patients compared to healthy controls, and were significantly down-regulated after tumor surgery (Ogata-Kawata et al., ?2014). However, miRNA expression profiling using qRT-PCR assays in 1) normal colorectal tissues, 2) adenoma and 3) CRC, MIR150 was found low down-regulated in all three groups and tumour tissue had reduced levels of MIR150 expression compared with paired non-cancerous tissue (Ma et al., ?2012).
  
  
Entity Esophageal cancer
Note MIR150 expression is significantly lower in esophageal squamous cell carcinoma (ESCC) samples compared with the normal esophageal mucosa levels (P < 0.001) (Yokobori et al., ?2013). It has been supposed that MIR150 suppresses tumor proliferation by degradation the Zinc finger E box binding homeobox 1 ( ZEB1).
  
  
Entity Gastric cancer
Note The probability of survival in gastric cancer is significantly lower in patients with high expression levels of MIR150 (Katada et al., 2009). MIR150 increases the proliferation rate of gastric cancer cells by targeting the tumor-suppressor early growth response factor 2 (EGR2) (Wu et al., ?2010).
  
  
Entity Breast cancer
Note High levels of MIR150 have been found in breast cancer tissues. The application of MIR150 inhibitors against breast cancer cell lines leads to apoptosis. There is a highly conserved MIR150-binding motif at the 3'UTR of P2X7 receptor (P2RX7 ID: 41623> ); MIR150 down-regulates the P2X7 protein levels and therefore causes the cancerous cells to escape from P2X7 pro-apoptotic control (Huang et al., ?2013).
  
  
Entity Lung cancer
Note Application of antisense oligonucleotide (ASO) against MIR150 in lung carcinoma cells A549 has induced the reduction of cell proliferation rates and increased apoptosis. Up-regulation of TP53 was detected after ASO treatment (Li et al., ?2012). MIR150 is upregulated in lung cancer and correlates negatively with the expression of TP53 (Zhang et al., ?2013). MIR150 regulates the expression of TP53 through binding to its 3'-UTR, thus inhibition of MIR150 leads to reduction of cell proliferation and increases apoptosis and expression of TP53. In another study, it was demonstrated that MIR150 represses SRC Kinase Signaling Inhibitor 1 (SRCIN1) which leads to the activation of the Src/focal adhesion kinase (PTK2 or FAK) and Src/Ras/extracellular signal-regulated kinase (ERK) pathway, and enhances the migration and proliferation rate of A549 cells (Cao et al., ?2014). Moreover, GU XY et al. showed that the overexpression of MIR150 in non-small-cell lung cancer (NSCLC) is associated with alterations in the expression of human BRI1-associated receptor kinase 1 (BAK1), so that inhibition of MIR150 reduces cell proliferation and promotes cell apoptosis (Gu et al., ?2014). However, it has been argued that the expression level of MIR150 in patients with small-cell lung cancer (SCLC) is much lower than normal lung samples (Bi et al., ?2014).
  
  
Entity Liver cancer
Note It has been suggested that MIR150 could be a suitable candidate to discriminate tumoural versus normal human primary hepatocytes (Di Masi et al., ?2010). In addition, it has been confirmed that the overexpression of MIR150 downregulates MYB protein levels and causes a significant reduction of CD133+ cells and the suppression of cell growth/tumorsphere formation (Zhang et al., ?2012). It is suggested that MIR150 may be engaged in the self-renewal of liver cancer stem cells through modulation of the downstream target MYB.
  
  
Entity Osteosarcoma
Note A nearly 50-fold overexpression of MIR150 in osteosarcoma samples compared to normal osteoblasts, has been reported (Lulla et al., ?2011). Upregulation of MIR150 may cause the down-regulation of P2X7 receptor and therefore an uncontrolled growth of osteosarcoma cells. Other study has argued that MIR150 inhibits cell proliferation and metastasis in osteosarcoma and stimulates cell apoptosis by regulating the expression of SP1 (Li et al., ?2015). Recently, it has been reported that MIR150 functions as a tumor suppressor in osteosarcoma partially by targeting the IGF2 mRNA-binding protein 1 (IGF2BP1) (Qu et al., ?2016).
  
  
Entity Hepatocellular carcinoma
Note In a recent attempt to identifying the role of miRNAs in hepatocellular carcinoma (HCC) progression, researchers have shown that there are low levels of miR-150-5p in cancerous samples, and determined that the inhibition of miR-150-5p has a drastic effect on hepatoma cell migration and invasion, whereas its overexpression shows reverse results (Li et al., ?2014). It was also confirmed that miR-150-5p inhibits the matrix metalloproteinase 14 (MMP14) expression in hepatoma cells.
  
  
Entity Prostate cancer
Note The high expression levels of MIR150 is positively correlated with tumor recurrence or metastasis (p=0.010) (Dezhong et al., ?2015). It was shown that prostate cancer patients with high MIR150 expression have significantly poorer overall survival and poorer disease-free survival compared those with low MIR150 expression. Furthermore, increased MIR150 expression might participate in the development and progression of human prostate cancer stem cells (CSC) via suppressing p27Kip1 (CDKN1B ) (Liu et al., ?2015).
  
  
Entity Intrahepatic cholangiocarcinoma
Note MIR150 is significantly downregulated in intrahepatic cholangiocarcinoma (ICC) tissues; however its expression level in the blood samples of ICC patients is significantly higher than in controls (Wang et al., ?2015).
  
  
Entity Burkitt lymphoma (BL)
Note MIR150 is dramatically down-regulated in BL patients; MYB and Survivin (BIRC5) are the targetrs of MIR150 (Wang et al., ?2014). In addition, MIR150 can induce Epstein Barr virus-positive BL differentiation by targeting MYB (Chen et al., ?2013).
  
  
Entity Cervical cancer
Note Interacting with 3' UTR of FOXO4, MIR150 reduces FOXO4 expression level and thereby regulates several cell cycle- and apoptosis- related genes (CyclinD1 (CCND1), p27, BCL2L11 (BIM), and FASLG), and leads to cervical cancer cell growth and survival (J Li et al., ?2015).
  
  
Entity Bladder cancer
Note An in vitro investigation to figuring out the role of MIR150 in cells has shown that MIR150 functions as a tumor promoter in reducing chemo-sensitivity and promoting invasiveness of muscle-invasive bladder cancer cells via targeting programmed cell death 4 protein (PDCD4) (Y Lei et al., ?2014).
  
  
Entity Epithelial ovarian cancer
Note A significant low expression level of MIR150 have been reported in epithelial ovarian cancer (EOC) tissues and patients' serum (Vang et al, ?2013; Shapira et al., ?2014). MIR150 may function as a tumor suppressor and modulate EOC cell proliferation, and invasion by directly and negatively regulating Zinc Finger E-Box Binding Homeobox 1 (ZEB1) (Jin et al., ?2014).
  
  
Entity Influenza
Note Patients with severe A/H1N1 disease exhibited a significant over-expression of circulating MIR150 than patients with milder disease, suggesting that the up-regulation of MIR150 is engaged with poorer outcomes of A/H1N1 infection (Morán et al., ?2015).
  
  
Entity Acquired immune deficiency syndrome (AIDS)
Note Down regulation of MIR150 during HIV infection and its lower level in CD4+ T cells of chronic HIV patients compared to healthy controls has been reported (Witwer et al., ?2012; Swaminathan et al., ?2009). It has been speculated that the suppression of MIR150 promotes HIV-1 infection (X Wang et al., ?2009). HIV positive patients can be grouped based on the MIR150 levels of their peripheral blood mononuclear cells or their plasma, suggesting MIR150 as a new biomarker for HIV progression, therapy and resistance (Munshi et al., ?2014).
  
  
Entity Dengue haemorrhagic fever (DHF)
Note The downregulation of suppressors of cytokine signaling 1 (SOCS1) proteins through transfection of a MIR150 mimic into CD14(+) cells infected with DENV-2, suggests that augmented MIR150 expression with depressed SOCS1 expression in CD14(+) cells is associated with the pathogenesis of DHF (RF Chen et al., ?2014).
  
  
Entity Cardiovascular Diseases
Note Low expression levels of MIR150 is associated with acute myocardial infarction, atrial fibrillation, dilated cardiomyopathy, ischaemic cardiomyopathy and various mouse heart failure models (Devaux et al., ?2013; Liu et al., ?2012; Topkara et al., ?2011; Duan et al., ?2013). MIR150 could be a better biomarker for HF than other markers used in clinic (Ellis et al., ?2013). MIR150 has a pivotal role as a regulator of cardiomyocyte survival during cardiac injury (Tang et al., ?2015). Reduced circulating MIR150 levels are associated with poor survival in pulmonary arterial hypertension (Rhodes et al., ?2013).
  
  
Entity Systemic sclerosis
Note MIR150 may play an important role in the pathogenesis of Systemic Sclerosis (SSc) via overexpression of integrin β 3 (ITGB3) (Honda et al., ?2013). MIR150 expression level is decreased in SSc fibroblasts and the treatment of normal fibroblasts with MIR150 inhibitor promotes the expression of integrin β3, phosphorylated SMAD3, and type I collagen. SSc patients with lower serum MIR150 levels show more severe clinical manifestations.
  
  
Entity Multiple sclerosis (MS)
Note MIR150 is down-regulated in peripheral blood mononuclear cells and T cells from MS patients (Martinelli-Boneschi et al., ?2012; Freiesleben et al., ?2016).
  

Bibliography

Beyond secondary structure: primary-sequence determinants license pri-miRNA hairpins for processing
Auyeung VC, Ulitsky I, McGeary SE, Bartel DP
Cell 2013 Feb 14;152(4):844-58
PMID 23415231
 
Human RNAi pathway: crosstalk with organelles and cells
Azimzadeh Jamalkandi S, Azadian E, Masoudi-Nejad A
Funct Integr Genomics 2014 Mar;14(1):31-46
PMID 24197738
 
Thrombopoietin regulates c-Myb expression by modulating micro RNA 150 expression
Barroga CF, Pham H, Kaushansky K
Exp Hematol 2008 Dec;36(12):1585-92
PMID 18814950
 
A microRNA signature predicts survival in early stage small-cell lung cancer treated with surgery and adjuvant chemotherapy
Bi N, Cao J, Song Y, Shen J, Liu W, Fan J, He J, Shi Y, Zhang X, Lu N, Zhan Q, Wang L
PLoS One 2014 Mar 17;9(3):e91388
PMID 24637927
 
Human microRNAs are processed from capped, polyadenylated transcripts that can also function as mRNAs
Cai X, Hagedorn CH, Cullen BR
RNA 2004 Dec;10(12):1957-66
PMID 15525708
 
miR-150 promotes the proliferation and migration of lung cancer cells by targeting SRC kinase signalling inhibitor 1
Cao M, Hou D, Liang H, Gong F, Wang Y, Yan X, Jiang X, Wang C, Zhang J, Zen K, Zhang CY, Chen X
Eur J Cancer 2014 Mar;50(5):1013-24
PMID 24456795
 
Augmented miR-150 expression associated with depressed SOCS1 expression involved in dengue haemorrhagic fever
Chen RF, Yang KD, Lee IK, Liu JW, Huang CH, Lin CY, Chen YH, Chen CL, Wang L
J Infect 2014 Oct;69(4):366-74
PMID 24907421
 
Re-expression of microRNA-150 induces EBV-positive Burkitt lymphoma differentiation by modulating c-Myb in vitro
Chen S, Wang Z, Dai X, Pan J, Ge J, Han X, Wu Z, Zhou X, Zhao T
Cancer Sci 2013 Jul;104(7):826-34
PMID 23521217
 
MicroRNA-150: a novel marker of left ventricular remodeling after acute myocardial infarction
Devaux Y, Vausort M, McCann GP, Zangrando J, Kelly D, Razvi N, Zhang L, Ng LL, Wagner DR, Squire IB
Circ Cardiovasc Genet 2013 Jun;6(3):290-8
PMID 23547171
 
miR-150 is a factor of survival in prostate cancer patients
Dezhong L, Xiaoyi Z, Xianlian L, Hongyan Z, Guohua Z, Bo S, Shenglei Z, Lian Z
J BUON 2015 Jan-Feb;20(1):173-9
PMID 25778313
 
Characterization of HuH6, Hep3B, HepG2 and HLE liver cancer cell lines by WNT/β - catenin pathway, microRNA expression and protein expression profile
Di Masi A, Viganotti M, Antoccia A, Magrelli A, Salvatore M, Azzalin G, Tosto F, Lorenzetti S, Maranghi F, Mantovani A, Macino G, Tanzarella C, Taruscio D
Cell Mol Biol (Noisy-le-grand) 2010 Jun 10;56 Suppl:OL1299-317
PMID 20937217
 
miR-150 regulates high glucose-induced cardiomyocyte hypertrophy by targeting the transcriptional co-activator p300
Duan Y, Zhou B, Su H, Liu Y, Du C
Exp Cell Res 2013 Feb 1;319(3):173-84
PMID 23211718
 
Circulating microRNAs as candidate markers to distinguish heart failure in breathless patients
Ellis KL, Cameron VA, Troughton RW, Frampton CM, Ellmers LJ, Richards AM
Eur J Heart Fail 2013 Oct;15(10):1138-47
PMID 23696613
 
Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet
Filipowicz W, Bhattacharyya SN, Sonenberg N
2008 Feb;9(2):102-14 doi: 10
PMID 18197166
 
MicroRNA biogenesis: isolation and characterization of the microprocessor complex
Gregory RI, Chendrimada TP, Shiekhattar R
Methods Mol Biol 2006;342:33-47
PMID 16957365
 
Down-regulation of miR-150 induces cell proliferation inhibition and apoptosis in non-small-cell lung cancer by targeting BAK1 in vitro
Gu XY, Wang J, Luo YZ, Du Q, Li RR, Shi H, Yu TP
Tumour Biol 2014 Jun;35(6):5287-93
PMID 24532468
 
miR-150 down-regulation contributes to the constitutive type I collagen overexpression in scleroderma dermal fibroblasts via the induction of integrin β3
Honda N, Jinnin M, Kira-Etoh T, Makino K, Kajihara I, Makino T, Fukushima S, Inoue Y, Okamoto Y, Hasegawa M, Fujimoto M, Ihn H
Am J Pathol 2013 Jan;182(1):206-16
PMID 23159943
 
miR-150 promotes human breast cancer growth and malignant behavior by targeting the pro-apoptotic purinergic P2X7 receptor
Huang S, Chen Y, Wu W, Ouyang N, Chen J, Li H, Liu X, Su F, Lin L, Yao Y
PLoS One 2013 Dec 2;8(12):e80707
PMID 24312495
 
MicroRNA regulate immune pathways in T-cells in multiple sclerosis (MS)
Jernås M, Malmeström C, Axelsson M, Nookaew I, Wadenvik H, Lycke J, Olsson B
BMC Immunol 2013 Jul 29;14:32
PMID 23895517
 
MicroRNA-150 predicts a favorable prognosis in patients with epithelial ovarian cancer, and inhibits cell invasion and metastasis by suppressing transcriptional repressor ZEB1
Jin M, Yang Z, Ye W, Xu H, Hua X
PLoS One 2014 Aug 4;9(8):e103965
PMID 25090005
 
microRNA expression profile in undifferentiated gastric cancer
Katada T, Ishiguro H, Kuwabara Y, Kimura M, Mitui A, Mori Y, Ogawa R, Harata K, Fujii Y
Int J Oncol 2009 Feb;34(2):537-42
PMID 19148490
 
The nuclear RNase III Drosha initiates microRNA processing
Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Rådmark O, Kim S, Kim VN
Nature 2003 Sep 25;425(6956):415-9
PMID 14508493
 
MicroRNA genes are transcribed by RNA polymerase II
Lee Y, Kim M, Han J, Yeom KH, Lee S, Baek SH, Kim VN
EMBO J 2004 Oct 13;23(20):4051-60
PMID 15372072
 
miR-150 modulates cisplatin chemosensitivity and invasiveness of muscle-invasive bladder cancer cells via targeting PDCD4 in vitro
Lei Y, Hu X, Li B, Peng M, Tong S, Zu X, Wang Z, Qi L, Chen M
Med Sci Monit 2014 Oct 7;20:1850-7
PMID 25287716
 
microRNA-150 promotes cervical cancer cell growth and survival by targeting FOXO4
Li J, Hu L, Tian C, Lu F, Wu J, Liu L
BMC Mol Biol 2015 Dec 29;16:24
PMID 26715362
 
miR-150-5p inhibits hepatoma cell migration and invasion by targeting MMP14
Li T, Xie J, Shen C, Cheng D, Shi Y, Wu Z, Zhan Q, Deng X, Chen H, Shen B, Peng C, Li H, Zhu Z
PLoS One 2014 Dec 30;9(12):e115577
PMID 25549355
 
MicroRNA-150 Inhibits Cell Invasion and Migration and Is Downregulated in Human Osteosarcoma
Li X, Chen L, Wang W, Meng FB, Zhao RT, Chen Y
Cytogenet Genome Res 2015;146(2):124-35
PMID 26361218
 
Regression of A549 lung cancer tumors by anti-miR-150 vector
Li YJ, Zhang YX, Wang PY, Chi YL, Zhang C, Ma Y, Lv CJ, Xie SY
Oncol Rep 2012 Jan;27(1):129-34
PMID 21935578
 
MIR-150 promotes prostate cancer stem cell development via suppressing p27Kip1
Liu DZ, Zhang HY, Long XL, Zou SL, Zhang XY, Han GY, Cui ZG
Eur Rev Med Pharmacol Sci 2015 Nov;19(22):4344-52
PMID 26636522
 
The expression levels of plasma micoRNAs in atrial fibrillation patients
Liu Z, Zhou C, Liu Y, Wang S, Ye P, Miao X, Xia J
PLoS One 2012;7(9):e44906
PMID 23028671
 
MicroRNA-mediated control of cell fate in megakaryocyte-erythrocyte progenitors
Lu J, Guo S, Ebert BL, Zhang H, Peng X, Bosco J, Pretz J, Schlanger R, Wang JY, Mak RH, Dombkowski DM, Preffer FI, Scadden DT, Golub TR
Dev Cell 2008 Jun;14(6):843-53
PMID 18539114
 
Identification of Differentially Expressed MicroRNAs in Osteosarcoma
Lulla RR, Costa FF, Bischof JM, Chou PM, de F Bonaldo M, Vanin EF, Soares MB
Sarcoma 2011;2011:732690
PMID 21789031
 
Substrate selectivity of exportin 5 and Dicer in the biogenesis of microRNAs
Lund E, Dahlberg JE
Cold Spring Harb Symp Quant Biol 2006;71:59-66
PMID 17381281
 
miR-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer
Ma Y, Zhang P, Wang F, Zhang H, Yang J, Peng J, Liu W, Qin H
Gut 2012 Oct;61(10):1447-53
PMID 22052060
 
MicroRNA and mRNA expression profile screening in multiple sclerosis patients to unravel novel pathogenic steps and identify potential biomarkers
Martinelli-Boneschi F, Fenoglio C, Brambilla P, Sorosina M, Giacalone G, Esposito F, Serpente M, Cantoni C, Ridolfi E, Rodegher M, Moiola L, Colombo B, De Riz M, Martinelli V, Scarpini E, Comi G, Galimberti D
Neurosci Lett 2012 Feb 2;508(1):4-8
PMID 22108567
 
Circulating levels of miR-150 are associated with poorer outcomes of A/H1N1 infection
Morán J, Ramírez-Martínez G, Jiménez-Alvarez L, Cruz A, Pérez-Patrigeon S, Hidalgo A, Orozco L, Martínez A, Padilla-Noriega L, Avila-Moreno F, Cabello C, Granados J, Ortíz-Quintero B, Ramírez-Venegas A, Ruíz-Palacios GM, Zlotnik A, Merino E, Zúñiga J
Exp Mol Pathol 2015 Oct;99(2):253-61
PMID 26148929
 
MicroRNA-150 is a potential biomarker of HIV/AIDS disease progression and therapy
Munshi SU, Panda H, Holla P, Rewari BB, Jameel S
PLoS One 2014 May 14;9(5):e95920
PMID 24828336
 
miRNAs on the move: miRNA biogenesis and the RNAi machinery
Murchison EP, Hannon GJ
Curr Opin Cell Biol 2004 Jun;16(3):223-9
PMID 15145345
 
Co-occurrence: A Gene Reference Resource for Coincidental Patterns of Gene Mutations in Human Cancers.
Nassiri I, Azadian E, Sharafi R, Masoudi-Nejad A.
J Proteomics Bioinform. 2013; 6:197-201. doi:10.4172/jpb.1000281
 
A Sequence Motif Associated with Intrinsic Mutation Hot-Spots in Human Cancers.
Nassiri I, Azadian E, Masoudi-Nejad A.
J Proteomics Bioinform. 2013; 6:183-186. doi:10.4172/jpb.1000279.
 
Circulating exosomal microRNAs as biomarkers of colon cancer
Ogata-Kawata H, Izumiya M, Kurioka D, Honma Y, Yamada Y, Furuta K, Gunji T, Ohta H, Okamoto H, Sonoda H, Watanabe M, Nakagama H, Yokota J, Kohno T, Tsuchiya N
PLoS One 2014 Apr 4;9(4):e92921
PMID 24705249
 
Dicer recognizes the 5' end of RNA for efficient and accurate processing
Park JE, Heo I, Tian Y, Simanshu DK, Chang H, Jee D, Patel DJ, Kim VN
Nature 2011 Jul 13;475(7355):201-5
PMID 21753850
 
MicroRNA-150 functions as a tumor suppressor in osteosarcoma by targeting IGF2BP1
Qu Y, Pan S, Kang M, Dong R, Zhao J
Tumour Biol 2016 Apr;37(4):5275-84
PMID 26561465
 
RNAstructure: software for RNA secondary structure prediction and analysis
Reuter JS, Mathews DH
BMC Bioinformatics 2010 Mar 15;11:129
PMID 20230624
 
Reduced microRNA-150 is associated with poor survival in pulmonary arterial hypertension
Rhodes CJ, Wharton J, Boon RA, Roexe T, Tsang H, Wojciak-Stothard B, Chakrabarti A, Howard LS, Gibbs JS, Lawrie A, Condliffe R, Elliot CA, Kiely DG, Huson L, Ghofrani HA, Tiede H, Schermuly R, Zeiher AM, Dimmeler S, Wilkins MR
Am J Respir Crit Care Med 2013 Feb 1;187(3):294-302
PMID 23220912
 
Circulating biomarkers for detection of ovarian cancer and predicting cancer outcomes
Shapira I, Oswald M, Lovecchio J, Khalili H, Menzin A, Whyte J, Dos Santos L, Liang S, Bhuiya T, Keogh M, Mason C, Sultan K, Budman D, Gregersen PK, Lee AT
Br J Cancer 2014 Feb 18;110(4):976-83
PMID 24366298
 
Inhibition of MUC4 expression suppresses pancreatic tumor cell growth and metastasis
Singh AP, Moniaux N, Chauhan SC, Meza JL, Batra SK
Cancer Res 2004 Jan 15;64(2):622-30
PMID 14744777
 
MicroRNA-150 directly targets MUC4 and suppresses growth and malignant behavior of pancreatic cancer cells
Srivastava SK, Bhardwaj A, Singh S, Arora S, Wang B, Grizzle WE, Singh AP
Carcinogenesis 2011 Dec;32(12):1832-9
PMID 21983127
 
Does the presence of anti-HIV miRNAs in monocytes explain their resistance to HIV-1 infection? Blood
Swaminathan S, Zaunders J, Wilkinson J, Suzuki K, Kelleher AD
2009 May 14;113(20):5029-30; author reply 5030-1 doi: 10
PMID 19443673
 
MicroRNA-150 protects the mouse heart from ischaemic injury by regulating cell death
Tang Y, Wang Y, Park KM, Hu Q, Teoh JP, Broskova Z, Ranganathan P, Jayakumar C, Li J, Su H, Tang Y, Ramesh G, Kim IM
Cardiovasc Res 2015 Jun 1;106(3):387-97
PMID 25824147
 
High-throughput oncogene mutation profiling in human cancer
Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, MacConaill L, Lee JC, Nicoletti R, Hatton C, Goyette M, Girard L, Majmudar K, Ziaugra L, Wong KK, Gabriel S, Beroukhim R, Peyton M, Barretina J, Dutt A, Emery C, Greulich H, Shah K, Sasaki H, Gazdar A, Minna J, Armstrong SA, Mellinghoff IK, Hodi FS, Dranoff G, Mischel PS, Cloughesy TF, Nelson SF, Liau LM, Mertz K, Rubin MA, Moch H, Loda M, Catalona W, Fletcher J, Signoretti S, Kaye F, Anderson KC, Demetri GD, Dummer R, Wagner S, Herlyn M, Sellers WR, Meyerson M, Garraway LA
Nat Genet 2007 Mar;39(3):347-51
PMID 17293865
 
Role of microRNAs in cardiac remodeling and heart failure
Topkara VK, Mann DL
Cardiovasc Drugs Ther 2011 Apr;25(2):171-82
PMID 21431305
 
Identification of ovarian cancer metastatic miRNAs
Vang S, Wu HT, Fischer A, Miller DH, MacLaughlan S, Douglass E, Comisar L, Steinhoff M, Collins C, Smith PJ, Brard L, Brodsky AS
PLoS One 2013;8(3):e58226
PMID 23554878
 
Role of microRNA-150 in solid tumors
Wang F, Ren X, Zhang X
Oncol Lett 2015 Jul;10(1):11-16
PMID 26170969
 
Low expression of miR-150 in pediatric intestinal Burkitt lymphoma
Wang M, Yang W, Li M, Li Y
Exp Mol Pathol 2014 Apr;96(2):261-6
PMID 24613688
 
Upregulated circulating miR-150 is associated with the risk of intrahepatic cholangiocarcinoma
Wang S, Yin J, Li T, Yuan L, Wang D, He J, Du X, Lu J
Oncol Rep 2015 Feb;33(2):819-25
PMID 25482320
 
Cellular microRNA expression correlates with susceptibility of monocytes/macrophages to HIV-1 infection
Wang X, Ye L, Hou W, Zhou Y, Wang YJ, Metzger DS, Ho WZ
Blood 2009 Jan 15;113(3):671-4
PMID 19015395
 
Relationships of PBMC microRNA expression, plasma viral load, and CD4+ T-cell count in HIV-1-infected elite suppressors and viremic patients
Witwer KW, Watson AK, Blankson JN, Clements JE
Retrovirology 2012 Jan 12;9:5
PMID 22240256
 
MiR-150 promotes gastric cancer proliferation by negatively regulating the pro-apoptotic gene EGR2
Wu Q, Jin H, Yang Z, Luo G, Lu Y, Li K, Ren G, Su T, Pan Y, Feng B, Xue Z, Wang X, Fan D
Biochem Biophys Res Commun 2010 Feb 12;392(3):340-5
PMID 20067763
 
MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb
Xiao C, Calado DP, Galler G, Thai TH, Patterson HC, Wang J, Rajewsky N, Bender TP, Rajewsky K
Cell 2007 Oct 5;131(1):146-59
PMID 17923094
 
MiR-150 is associated with poor prognosis in esophageal squamous cell carcinoma via targeting the EMT inducer ZEB1
Yokobori T, Suzuki S, Tanaka N, Inose T, Sohda M, Sano A, Sakai M, Nakajima M, Miyazaki T, Kato H, Kuwano H
Cancer Sci 2013 Jan;104(1):48-54
PMID 23013135
 
microRNA-150 inhibits human CD133-positive liver cancer stem cells through negative regulation of the transcription factor c-Myb
Zhang J, Luo N, Luo Y, Peng Z, Zhang T, Li S
Int J Oncol 2012 Mar;40(3):747-56
PMID 22025269
 
miR-150 promotes the proliferation of lung cancer cells by targeting P53
Zhang N, Wei X, Xu L
FEBS Lett 2013 Aug 2;587(15):2346-51
PMID 23747308
 
Secreted monocytic miR-150 enhances targeted endothelial cell migration
Zhang Y, Liu D, Chen X, Li J, Li L, Bian Z, Sun F, Lu J, Yin Y, Cai X, Sun Q, Wang K, Ba Y, Wang Q, Wang D, Yang J, Liu P, Xu T, Yan Q, Zhang J, Zen K, Zhang CY
Mol Cell 2010 Jul 9;39(1):133-44
PMID 20603081
 

Citation

This paper should be referenced as such :
Arjmand M
MIR150;
Atlas Genet Cytogenet Oncol Haematol. in press
On line version : http://AtlasGeneticsOncology.org/Genes/MIR150ID50556ch19q13.html


Other Solid tumors implicated (Data extracted from papers in the Atlas) [ 1 ]
  Head and Neck: Salivary gland tumors: an overview


External links

Nomenclature
HGNC (Hugo)MIR150   31537
Cards
AtlasMIR150ID50556ch19q13
Entrez_Gene (NCBI)MIR150  406942  microRNA 150
AliasesMIRN150; miRNA150; mir-150
GeneCards (Weizmann)MIR150
Ensembl hg19 (Hinxton) [Gene_View]
Ensembl hg38 (Hinxton) [Gene_View]  chr19:49500785-49500868 [Contig_View]  MIR150 [Vega]
TCGA cBioPortalMIR150
AceView (NCBI)MIR150
Genatlas (Paris)MIR150
WikiGenes406942
SOURCE (Princeton)MIR150
Genetics Home Reference (NIH)MIR150
miRBaseMIR150
dbDEMCMIR150
Genomic and cartography
GoldenPath hg38 (UCSC)MIR150  -     chr19:49500785-49500868 -  19q13.33   [Description]    (hg38-Dec_2013)
GoldenPath hg19 (UCSC)MIR150  -     19q13.33   [Description]    (hg19-Feb_2009)
EnsemblMIR150 - 19q13.33 [CytoView hg19]  MIR150 - 19q13.33 [CytoView hg38]
Mapping of homologs : NCBIMIR150 [Mapview hg19]  MIR150 [Mapview hg38]
OMIM611114   
Gene and transcription
Genbank (Entrez)LM608519
RefSeq transcript (Entrez)
RefSeq genomic (Entrez)
Consensus coding sequences : CCDS (NCBI)MIR150
Gene ExpressionMIR150 [ NCBI-GEO ]   MIR150 [ EBI - ARRAY_EXPRESS ]   MIR150 [ SEEK ]   MIR150 [ MEM ]
Gene Expression Viewer (FireBrowse)MIR150 [ Firebrowse - Broad ]
SOURCE (Princeton)Expression in : [Datasets]   [Normal Tissue Atlas]  [carcinoma Classsification]  [NCI60]
BioGPS (Tissue expression)406942
GTEX Portal (Tissue expression)MIR150
Protein : pattern, domain, 3D structure
Domain families : Pfam (Sanger)
Domain families : Pfam (NCBI)
Conserved Domain (NCBI)MIR150
DMDM Disease mutations406942
Blocks (Seattle)MIR150
Protein Interaction databases
BioGRIDMIR150
STRING (EMBL)MIR150
ZODIACMIR150
Ontologies - Pathways
Huge Navigator MIR150 [HugePedia]
snp3D : Map Gene to Disease406942
BioCentury BCIQMIR150
ClinGenMIR150
Clinical trials, drugs, therapy
Chemical/Protein Interactions : CTD406942
Chemical/Pharm GKB GenePA164722506
Clinical trialMIR150
Miscellaneous
canSAR (ICR)MIR150 (select the gene name)
Probes
Litterature
PubMed98 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
CoreMineMIR150
EVEXMIR150
GoPubMedMIR150
iHOPMIR150
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Wed Nov 15 12:27:16 CET 2017

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.